EULAR/ACR Systemic Lupus Erythematosus Classification Criteria Update
EULAR and ACR jointly funded and collaborated on creating a set of criteria that can be used to more accurately identify patients with SLE for inclusion in clinical trials.
EULAR and ACR jointly funded and collaborated on creating a set of criteria that can be used to more accurately identify patients with SLE for inclusion in clinical trials.
While a treat to target strategy has been proposed for managing SLE, the impact of possible disease outcomes has not been fully evaluated.
Use of the anti-apoptotic protein B-cell lymphoma 2 inhibitor venetoclax reduced total lymphocyte and disease-relevant B cells in women with SLE.
These guidelines address the use of antirheumatic drugs for adults with RA, SpA, JIA, and SLE undergoing THA or TKA.
The new approach in development proposes the use of positive indirect immunofluorescence ANA (IIF-ANA) as an entry criterion for SLE classification.
Increased disease activity, poorer physical functioning, and lower education attainment were major predictors for depression in adulthood.
Meta-analysis supports anti-RNP and anti-Sm antibodies as serological biomarkers of PAH risk in patients with systemic lupus erythematosus.
MOCA is more effective than the Mini-Mental State Examination at detecting cognitive dysfunction.
The majority of patients with systemic lupus erythematosus have poor quality of sleep.
Cumulative steroid dosage is a risk factor for the development of osteonecrosis.